Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


July 21, 2010  

FDA’s Partial Hold on Unethical Diabetes Drug Trial Does Not Do Enough to Protect Patients

Statement of Dr. Sidney Wolfe, Director, Public Citizen’s Health Research Group

The Food and Drug Administration (FDA) has gone only half-way in stopping the unethical TIDE study by halting the recruitment of any new patients. To allow the experiment to continue at all is a major breach in the FDA’s obligation to protect people in clinical trials. In May of this year, we wrote to the FDA urging a complete cessation of the TIDE trial. In late 2008, we petitioned the FDA to ban the diabetes drug rosiglitazone, better known as Avandia.

By stating that “Patients already enrolled in the trial will be allowed to continue to participate,” the FDA is failing to protect the more than 1,100 people already enrolled in the trial from the needless damage that will occur to those randomized to get rosiglitazone instead of pioglitazone, commonly known as Actos.

As the Institute of Medicine told the FDA last week, when new information concerning a drug becomes available, the participants need to be informed. How many of these 1,100 people would drop out of the study if they were told, for example, that an FDA advisory committee voted 21 to 3 (with 9 unsure) that the heart risks of rosiglitazone are greater than those of pioglitazone? This compounds the previous lack of informed consent about the two key facts – that an expert committee of the American Diabetes Association unanimously concluded that Avandia should not be used for treating diabetes and that there has been more than an 80 percent decrease in prescriptions for the drug.

By failing to completely stop the TIDE trial and to ban the drug, the FDA is not only guaranteeing that the 1,100 patients in the TIDE trial continue to be subjected to an unacceptably dangerous drug, but also hundreds of thousands of people will continue to use the drug in this country.

 To read Public Citizen’s letter to the FDA, sent in May, to stop the TIDE trial, visit: http://www.citizen.org/Page.aspx?pid=3312.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.